JPS6312043B2 - - Google Patents
Info
- Publication number
- JPS6312043B2 JPS6312043B2 JP52127469A JP12746977A JPS6312043B2 JP S6312043 B2 JPS6312043 B2 JP S6312043B2 JP 52127469 A JP52127469 A JP 52127469A JP 12746977 A JP12746977 A JP 12746977A JP S6312043 B2 JPS6312043 B2 JP S6312043B2
- Authority
- JP
- Japan
- Prior art keywords
- pseudomonic acid
- mycoplasma
- diseases
- salts
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 34
- 229960003128 mupirocin Drugs 0.000 claims description 34
- 229930194369 pseudomonic acid Natural products 0.000 claims description 34
- MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 10
- -1 alkali metal salt Chemical class 0.000 claims description 9
- 244000144977 poultry Species 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 241001430197 Mollicutes Species 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 241000202946 Mycoplasma pulmonis Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000004712 air sac Anatomy 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 241000202942 Mycoplasma synoviae Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002725 anti-mycoplasma Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- SHCFCJUJGBRSPO-UHFFFAOYSA-N 1-cyclohexylcyclohexan-1-amine Chemical compound C1CCCCC1C1(N)CCCCC1 SHCFCJUJGBRSPO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 241000006377 Mycoplasma dispar Species 0.000 description 1
- 241000202952 Mycoplasma fermentans Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000287182 Sturnidae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010064921 Urinary tract inflammation Diseases 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯äŒæç
ãç¹ã«ãã以å€ã®åºä¹³åç©ãã
ã³å®¶çŠœã®ããçš®ã®çŽ°èæ§äŒæç ã®æ²»çæ³ã«é¢ãã
ãã®ã§ããã ããœã€ãã¢ã³é žïŒPseudomonic acidïŒã¯åŒ
ïŒïŒ ã§ç€ºãããæ§é ã®ïŒ¥âç°æ§äœã§ãã€ãŠãè±åœç¹èš±
第1395907å·æ现æžã«æèæ§ãæãããšèšèŒãã
ãŠãããæ¬çºæã«ãããŠãããœã€ãã¢ã³é žãã€ã³
ãã«ãšã³ã¶èïŒHaemophilus influenzaeïŒãªã³
åçèïŒNeisseria gonorrhoeaeïŒããã³ãã€ã³
ãã©ãºãèïŒMy coplasmaïŒã«å¯ŸããŠç¹ã«é«ã
æèæ§ãæããŠããã®ã§ãåŒåžåšç³»çŸç ãæ§ç ã
ãã³ãã€ã³ãã©ãºãèã«èµ·å ãã家犜ã®çŸç ã®æ²»
çã«å¹æãããããšãããã€ãã æ¬çºæã«ããã°ãåŒïŒïŒã®ããœã€ãã¢ã³é žãŸ
ãã¯ãã®éæ¯æ§å¡©ãŸãã¯ãšã¹ãã«ã®æå¹éããã
ã¢ãã€ã©ã¹å±ïŒHaemophilusïŒããã³ãã€ã»ãª
ã¢å±ïŒNeisseriaïŒã®èã«èµ·å ããåŒåžåšç³»çŸç
ããã³æ§ç ãããã³ãã€ã³ãã©ãºã
ïŒMycoplasmaïŒã«èµ·å ããçŸç ã«ããã€ããã
以å€ã®åºä¹³åç©ã䞊ã³ã«ãã€ã³ãã©ãºãã«èµ·å ã
ãçŸç ã«ããã€ã家犜ã«æäžããããšãããªãã
ã以å€ã®åºä¹³åç©ããã³å®¶çŠœã®çŸç ãæ²»çããæ¹
æ³ãåŸãããã ããœã€ãã¢ã³é žã¯åŒïŒïŒ¡ïŒ ã§ç€ºããããããªçµ¶äœç«äœååŠãæãããšä¿¡ãã
ããŠããã æäžå¯èœãªããœã€ãã¢ã³é žã®å¥œé©ãªéæ¯æ§å¡©ã«
ã¯ãéå±å¡©ããšãã°ã¢ã«ãããŠã å¡©ãã¢ã«ã«ãªé
å±å¡©ããšãã°ãããªãŠã å¡©ãããã¯ã«ãªãŠã å¡©ã
ã¢ã«ã«ãªåæå¡©ããšãã°ã«ã«ã·ãŠã å¡©ãããã¯ã
ã°ãã·ãŠã å¡©ãã¢ã³ã¢ããŠã å¡©ãŸãã¯çœ®æã¢ã³ã¢
ããŠã å¡©ããšãã°ããªãšãã«ã¢ãã³ã®ãããªäœçŽ
ã¢ã«ãã«ã¢ãã³å¡©ãïŒâããããªãã·ãšãã«ã¢ã
ã³ããã¹âïŒïŒâããããªãã·ãšãã«ïŒâã¢ãã³
ãããã¯ããªâïŒïŒâããããªãã·ãšãã«ïŒâã¢
ãã³ã®ãããªããããªãã·äœçŽã¢ã«ãã«ã¢ãã³
å¡©ããã·ã¯ãããã·ã«ã¢ãã³ã®ãããªã·ã¯ãã¢ã«
ãã«ã¢ãã³å¡©ããŸãã¯ããã«ã€ã³ããžãã³ãžã«ã¢
ãã³ãïŒïŒ®âãžãã³ãžã«ãšãã¬ã³ãžã¢ãã³ãïŒ
âãšããšããã³ãâãšãã«ãããªãžã³ãâã
ã³ãžã«âβâããšããã«âã¢ãã³ãããããã¢ã
ãšãã«ã¢ãã³ãããã¯ïŒ®ïŒNâ²âãã¹ããããã¢
ããšãã«ãšãã¬ã³ãžã¢ãã³å¡©ããŸãã¯ããªãžã³ã
ã³ãªãžã³ãããã¯ãããªã³ã®ãããªããªãžã³ç³»ã®
å¡©åºãšã®å¡©ãããã 奜ãŸããå¡©ã¯ã¢ã«ã«ãªéå±å¡©ã§ããã 奜é©ãªãšã¹ãã«ã¯é眮æãŸãã¯ããããªãã·ã
ã¢ãããŸãã¯ããã²ã³åºã§çœ®æãããã¢ã«ãã«ã
ã¢ãªãŒã«ããã³ã¢ã«ã¢ã«ãã«ãšã¹ãã«ããããã
ãšãã°ãšã¹ãã«åºã¯C1ãC6ã®ã¢ã«ãã«åºãç¹ã«
ã¡ãã«ããšãã«ãïœâãããã«ãã€ãœãããã«ã
ïœâããã«ãsecâããã«ãã€ãœããã«ãããã¯
ïœâããã«ããããŒïŒC1ãC6ïŒã¢ã«ãã«åºããš
ãã°ããªãã«ãªãã¡ãã«ãïŒïŒïŒïŒïŒâããªã¯ã
ããšãã«ãã¢ããã¢ã«ãã«åºããšãã°ã¢ããã¡ã
ã«ãïŒâã¢ãããšãã«ãããããªãã·ã¢ã«ãã«åº
ããšãã°ããããªãã·ã¡ãã«ãããããªãã·ãšã
ã«ãããšãã«ã眮æããšãã«ããŸãã¯ãã³ãžã«åº
ã§ããã 奜ãŸãããšã¹ãã«ã¯C1ãC6ã¢ã«ãã«ãšã¹ãã«
ã§ããã ããœã€ãã¢ã³é žããã®å¡©ããã³ãã®ãšã¹ãã«ã
ç¹ã«æå¹ãªäŒæç ã«ã¯æ§ç ããããããœã€ãã¢ã³
é žã¯Î²âã©ã¯ã¿ã æ§é ã®æèå€ã§ã¯ãªãã®ã§ãã
ãã·ãªã³ããã³ã»ãã¢ãã¹ããªã³æèå€ã䜿çšã§
ããªããªã³åçèã®Î²âã©ã¯ã¿ããŒãŒèæ ªã«å¯Ÿã
ãŠå¹æããããããœã€ãã¢ã³é žã¯ãŸãåŒåžåšç ã
ãšãã°æ ¢æ§æ°ç®¡æ¯çããã³çŽ°èæ§ãºã€èçãéãª
ã³èæ§å°¿éçããã³èºçã®æ²»çã«ãå¹æãããã
ç¹ã«åç©ã®å Žåãããœã€ãã¢ã³é žã¯çé·ä¿é²å€ãš
ããŠããŸãã¯ä¹³çã®ä¹³è ºçã®æ²»çããã³äžé¢é³¥ã
ãã¯ããªããã³ãã¿ã®ãããªåç©ã®ãã€ã³ãã©ãº
ãæ§äŒæç ã®æ²»çã«äœ¿çšããããšãã§ããã ãã€ã³ãã©ãºãèã«ãã€ãŠèµ·ããããœã€ãã¢ã³
é žããã³ãã®å¡©ããã³ãšã¹ãã«ãå¹æã瀺ã家ç
ããã³å®¶çŠœã®çŸç ãè¥å¹²ç€ºããšæ¬¡ã®åŠããªãã é³¥ é¡ ãã€ã³ãã©ãºãã»ã¬ãªã»ããã€ã«ã ïŒM.gall
âisepticumïŒâãã¯ããªããã³äžé¢é³¥ã®æ ¢æ§åŒ
åžåšç ãæ°ã®ãçŸæ£ïŒairsacculitiesïŒã ãã€ã³ãã©ãºãã»ã·ããã¢ãšïŒM.synoviaeïŒ
âæ°ã®ãçŸæ£ããã³æææ§æ»èç
ïŒinfectionssynovitisïŒ ãŠ ã· ãã€ã³ãã©ãºãã»ããã¹ïŒM.BovisïŒâä¹³çã®
ä¹³è ºçãåŒåžåšç ããã³é¢ç¯ç ãã€ã³ãã©ãºãã»ãã€ã¹ããŒã«ïŒM.disparïŒ
âåçã®èºç ãã¿é¡ ãã€ã³ãã©ãºãã»ã¹ã€ããŠãŒã¢ãã¢ãšïŒM.
suipneumoniaeïŒâè±ã®æµè¡æ§èºç ããºãé¡ ãã€ã³ãã©ãºãã»ãã«ã¢ãã¹ïŒM.pulmonisïŒ
âã©ããããã³ããã«ããºãã®èºç ãã€ã³ãã©ãºãã»ãã«ã¢ãã¹âJ.Bââããã«
ããºãã®é¢ç¯çäœµçº ã ã ãã€ã³ãã©ãºãã»ããŠãŒã¢ãã¢ãšïŒM.
pneumoniaeïŒâåçºæ§ç°åèºç ãã€ã³ãã©ãºãã»ããšã«ã¡ã³ã¿ã³ã¹ïŒM.
fermentansïŒ MWK14âãªãŠããæ§æ£è ã®é¢ç¯ããåé¢ããœ
ã€ãã¢ã³é žã¯ãã¿ãåçããã³ãããžã®ãããªå
ç©ã®æµè¡æ§èºçã«èªçºãããŠåŒåžåšã®å䜵çã
æã ã²ãããããã«ãããŒã©ïŒããã³ãã»ããã«
ïŒBordetella bronchisepticaïŒããã³ãã¹ããŠã¬
ã©ïŒã ã«ãã·ãïŒPasteurlla multotidaïŒèã«å¯Ÿ
ããŠãæèæ§ãæããã®ã§ããã®èºçã®æ²»çã«ç¹
ã«æçšã§ããã ããœã€ãã¢ã³é žãŸãã¯ãã®å¡©ãŸãã¯ãšã¹ãã«ã¯
家çå»è¬ãšããŠäœ¿çšãããããä»»æã®éœåã®ãã
æ¹æ³ã§èª¿å€ããããšãã§ããã çµæç©ã¯ä»»æã®çµè·¯ãéã€ãŠæäžããããã«èª¿
å€ããããšãã§ããæ²»çããããšããçŸç ã«ãã€
ãŠå€ãããçµæç©ã¯é å€ãã«ãã»ã«å€ãç²æ«å€ã
é¡ç²å€ãããããå€ãŸãã¯çµå£çšãŸãã¯æ» èéçµ
å£æº¶æ¶²ãŸãã¯æžæ¿å€ã®ãããªæ¶²äœè£œå€ã®åœ¢ã«ãã
ããšãã§ããã é å€ããã³ã«ãã»ã«å€ã¯åäœæäžåœ¢ãšããããš
ãã§ããéåžžã®äœè¬ãããšãã°ã·ããããã¢ã©ã
ã€ãŽã ããŒã©ãã³ããœã«ãããŒã«ããã©ã¬ã«ã³ã
ãŽã ãŸãã¯ããªããã«ãããªãã³ã®ãããªçµå
å€ãä¹³ç³ãã·ãšç³ãããŠã¢ãã³ã·æ®¿ç²ããªã³é žã«
ã«ã·ãŠã ããœã«ãããŒã«ãŸãã¯ã°ãªã·ã³ã®ãããª
å å¡«å€ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãæ»ç³ç²ãã
ãªãšãã¬ã³ã°ãªã³ãŒã«ãŸãã¯ã·ãªã«ã®ãããªé å€
補é ã®ãšãã®æœ€æ»å€ããã¬ã€ã·ãšæ®¿ç²ã®ãããªåŽ©
å£å€ããŸãã¯ã©ãŠãªã«ç¡«é žãããªãŠã ã®ãããªå»
çšã«äŸãåŸã湿最å€ãå ¥ããããšãã§ãããé å€
ã¯éåžžã®è£œè¬ã§å®æœãããŠããåšç¥ã®æ¹æ³ã«åŸã€
ãŠè¢«èŠããããšãã§ãããçµå£æ¶²äœè£œå€ã¯ãããš
ãã°æ°Žæ§ãŸãã¯æ²¹æ§ã®æžæ¿æ¶²ã溶液ã乳液ãã·ã
ããå€ãŸãã¯ãšãªãã·ã«ã®åœ¢ã«ããããšãã§ãã
ãããã¯ä¹Ÿç¥è£œåã®åœ¢ã«ããŠäœ¿çšåã«æ°Žãã®ä»ã®
é©åœãªããã¯ã«ã䜿çšããŠåæ§æããããšãã§ã
ãããã®çš®ã®æ¶²äœè£œå€ã¯éåžžã®æ·»å å€ãããšãã°
ãœã«ãããŒã«ãã·ããããã¡ãã«ã»ã«ããŒã¹ãã
ããŠç³ã·ãããããŒã©ãã³ãŸãã¯æ°ŽçŽ æ·»å é£ææ²¹
èã®ãããªæžæ¿å€ãã¬ã·ãã³ãã¢ããªã¬ã€ã³é žãœ
ã«ãã¿ã³ãŸãã¯ã¢ã©ãã€ãŽã ã®ãããªä¹³åå€ãæ
æ¡æ²¹ãåçã€ã·æ²¹ãã°ãªã»ãªã³ããããã¬ã³ãŸã
ã¯ãšãã«ã¢ã«ã³ãŒã«ã®ãšã¹ãã«ã®ãããªæ²¹ç¶ãšã¹
ãã«ã®ãããªé£ææ²¹ãå«ãéæ°Žæ§ããã¯ã«ãâ
ããããªãã·å®æ¯éŠé žã¡ãã«ãŸãã¯ãããã«ãŸã
ã¯ãœã«ãã³é žã®ãããªé²è å€ããã³å Žåã«ãã€ãŠ
ã¯é垞䜿çšãããŠãã颚å³æããã³çè²å€ãå«ã
ããšãã§ããã 座è¬ã¯éåžžã®åº§è¬çšåºå€ãããšãã°ã³ã³ã¢ãã¿
ãŒãã®ä»ã®ã°ãªã»ãªããå«ãã éçµå£æäžçšã®æ¶²ç¶åäœéæäžåœ¢ã¯ååç©ãã
ã³æ» èããã¯ã«ã奜ãŸããã¯æ°Žã䜿çšããŠèª¿è£œã
ãããååç©ã¯äœ¿çšããã¯ã«ããã³æ¿åºŠã«å¿ããŠ
ããã¯ã«æžæ¿ããããããããã¯æº¶è§£ãããã溶
液ã«ããå Žåã«ã¯ãååç©ã泚å°çšã®æ°Žã«ãšã
ãããéæ» èããŠããé©åœãªãã¢ã«ãŸãã¯ã¢ã³ã
ã«å å¡«ããã·ãŒã«ãããå±éšéº»é å€ãé²è å€ãã
ã³ç·©è¡å€ã®ãããªè£å©å€ãããã¯ã«ã«æº¶è§£ãããŠ
ãããšæå©ã§ãããçµæç©ã®å®å®æ§ãåäžããã
ããã«ããã¢ã«ã«å å¡«ããŠããåçµããæ°Žãç空
é€å»ããã次ã«åçµä¹Ÿç¥ç²æ«ããã¢ã«ã«å¯å°ãã
泚å°çšæ°Žã®ãã¢ã«ãæ·»ä»ããŠäœ¿çšåã«æ¶²äœè£œå€ã«
åæ§æãããéçµå£æžæ¿æ¶²ãå®è³ªçã«åæ§ã«èª¿è£œ
ãããããååç©ã溶解ãããªãã§ããã¯ã«ã«æž
æ¿ãããç¹ãšæ» èããéã§è¡ãªãããšãã§ããªã
ç¹ãšãã¡ãããååç©ã¯æ» èããã¯ã«ã«æžæ¿ãã
ãåã«é žåãšãã¬ã³ã«ãããããšã«ãã€ãŠæ» èã
ãããšãã§ãããååç©ãåäžã«åæ£ããããã
ãããã«ãçµæç©ã«è¡šé¢æŽ»æ§å€ãŸãã¯æ¹¿æœ€å€ãå ¥
ãããšæå©ã§ããã çµæç©ã¯æäžæ¹æ³ã«å¿ããŠæŽ»æ§ç©è³ª0.1ã99é
éïŒ ã奜ãŸããã¯10ã60ééïŒ ãå«ãããšãã§ã
ããçµæç©ãåäœæäžéã®åœ¢ã§ããå Žåã«ã¯åãŠ
ãããã¯å¥œãŸããã¯æŽ»æ§æå50ã500mgãå«ãã
æ人ã®æ²»çã«äœ¿çšããããšãã®æäžéã¯æäžçµè·¯
ããã³é »åºŠã«å¿ããŠã奜ãŸããã¯100mgãïŒïœïŒ
æ¥ãããšãã°250mgãïŒïœïŒæ¥ãšããã å¥æ³ãšããŠãããœã€ãã¢ã³é žãŸãã¯ãã®å¡©ãŸã
ã¯ãšã¹ãã«ã¯é£é€å šäœã®äžéšãšããŠæäžããããš
ãã§ããããã®å Žåååç©ã®äœ¿çšéã¯é£é€ã®ïŒé
éïŒ ã奜ãŸããã¯0.5ééïŒ ä»¥äžã§ãããåç©çš
ã®é£é€ã¯éåžžã®é£ç©ã«ååç©ãå ãããã®ã«ãã
ãããããã¯ååç©ããã¬ããã¯ã¹ã«å ããããš
ãã§ããã çç©åŠçããŒã¿ ïŒ ææµææ¢æ¿åºŠïŒMICå€ïŒ 第ïŒè¡šã¯ããœã€ãã¢ã³é žã®æèã¹ãã¯ãã«ã瀺
ããããœã€ãã¢ã³é žã¯ãããŠç¶çèå±ããã³å€§éš
åã®é£éç¶çèå±ã®çŽ°èã«å¯ŸããŠè¯å¥œãªæèæ§ã
æãããä»ã®æçç©è³ªã«å¯ŸããŠæµææ§ãæããè
æ ªãå«ãåçèå±èããã³ã€ã³ãã«ãšã³ã¶èã¯æ¬
ååç©ã«éåžžã«ææã§ãããç¹ã«ããã€ã³ãã©ãº
ãèæ ªã¯ããœã€ãã¢ã³é žã«éåžžã«ææã§ãããã
ãœã€ãã¢ã³é žã¯ã°ã©ã é°æ§èã«å¯ŸããŠæ¯èŒçã«äž
掻æ§ã§ããã
ã³å®¶çŠœã®ããçš®ã®çŽ°èæ§äŒæç ã®æ²»çæ³ã«é¢ãã
ãã®ã§ããã ããœã€ãã¢ã³é žïŒPseudomonic acidïŒã¯åŒ
ïŒïŒ ã§ç€ºãããæ§é ã®ïŒ¥âç°æ§äœã§ãã€ãŠãè±åœç¹èš±
第1395907å·æ现æžã«æèæ§ãæãããšèšèŒãã
ãŠãããæ¬çºæã«ãããŠãããœã€ãã¢ã³é žãã€ã³
ãã«ãšã³ã¶èïŒHaemophilus influenzaeïŒãªã³
åçèïŒNeisseria gonorrhoeaeïŒããã³ãã€ã³
ãã©ãºãèïŒMy coplasmaïŒã«å¯ŸããŠç¹ã«é«ã
æèæ§ãæããŠããã®ã§ãåŒåžåšç³»çŸç ãæ§ç ã
ãã³ãã€ã³ãã©ãºãèã«èµ·å ãã家犜ã®çŸç ã®æ²»
çã«å¹æãããããšãããã€ãã æ¬çºæã«ããã°ãåŒïŒïŒã®ããœã€ãã¢ã³é žãŸ
ãã¯ãã®éæ¯æ§å¡©ãŸãã¯ãšã¹ãã«ã®æå¹éããã
ã¢ãã€ã©ã¹å±ïŒHaemophilusïŒããã³ãã€ã»ãª
ã¢å±ïŒNeisseriaïŒã®èã«èµ·å ããåŒåžåšç³»çŸç
ããã³æ§ç ãããã³ãã€ã³ãã©ãºã
ïŒMycoplasmaïŒã«èµ·å ããçŸç ã«ããã€ããã
以å€ã®åºä¹³åç©ã䞊ã³ã«ãã€ã³ãã©ãºãã«èµ·å ã
ãçŸç ã«ããã€ã家犜ã«æäžããããšãããªãã
ã以å€ã®åºä¹³åç©ããã³å®¶çŠœã®çŸç ãæ²»çããæ¹
æ³ãåŸãããã ããœã€ãã¢ã³é žã¯åŒïŒïŒ¡ïŒ ã§ç€ºããããããªçµ¶äœç«äœååŠãæãããšä¿¡ãã
ããŠããã æäžå¯èœãªããœã€ãã¢ã³é žã®å¥œé©ãªéæ¯æ§å¡©ã«
ã¯ãéå±å¡©ããšãã°ã¢ã«ãããŠã å¡©ãã¢ã«ã«ãªé
å±å¡©ããšãã°ãããªãŠã å¡©ãããã¯ã«ãªãŠã å¡©ã
ã¢ã«ã«ãªåæå¡©ããšãã°ã«ã«ã·ãŠã å¡©ãããã¯ã
ã°ãã·ãŠã å¡©ãã¢ã³ã¢ããŠã å¡©ãŸãã¯çœ®æã¢ã³ã¢
ããŠã å¡©ããšãã°ããªãšãã«ã¢ãã³ã®ãããªäœçŽ
ã¢ã«ãã«ã¢ãã³å¡©ãïŒâããããªãã·ãšãã«ã¢ã
ã³ããã¹âïŒïŒâããããªãã·ãšãã«ïŒâã¢ãã³
ãããã¯ããªâïŒïŒâããããªãã·ãšãã«ïŒâã¢
ãã³ã®ãããªããããªãã·äœçŽã¢ã«ãã«ã¢ãã³
å¡©ããã·ã¯ãããã·ã«ã¢ãã³ã®ãããªã·ã¯ãã¢ã«
ãã«ã¢ãã³å¡©ããŸãã¯ããã«ã€ã³ããžãã³ãžã«ã¢
ãã³ãïŒïŒ®âãžãã³ãžã«ãšãã¬ã³ãžã¢ãã³ãïŒ
âãšããšããã³ãâãšãã«ãããªãžã³ãâã
ã³ãžã«âβâããšããã«âã¢ãã³ãããããã¢ã
ãšãã«ã¢ãã³ãããã¯ïŒ®ïŒNâ²âãã¹ããããã¢
ããšãã«ãšãã¬ã³ãžã¢ãã³å¡©ããŸãã¯ããªãžã³ã
ã³ãªãžã³ãããã¯ãããªã³ã®ãããªããªãžã³ç³»ã®
å¡©åºãšã®å¡©ãããã 奜ãŸããå¡©ã¯ã¢ã«ã«ãªéå±å¡©ã§ããã 奜é©ãªãšã¹ãã«ã¯é眮æãŸãã¯ããããªãã·ã
ã¢ãããŸãã¯ããã²ã³åºã§çœ®æãããã¢ã«ãã«ã
ã¢ãªãŒã«ããã³ã¢ã«ã¢ã«ãã«ãšã¹ãã«ããããã
ãšãã°ãšã¹ãã«åºã¯C1ãC6ã®ã¢ã«ãã«åºãç¹ã«
ã¡ãã«ããšãã«ãïœâãããã«ãã€ãœãããã«ã
ïœâããã«ãsecâããã«ãã€ãœããã«ãããã¯
ïœâããã«ããããŒïŒC1ãC6ïŒã¢ã«ãã«åºããš
ãã°ããªãã«ãªãã¡ãã«ãïŒïŒïŒïŒïŒâããªã¯ã
ããšãã«ãã¢ããã¢ã«ãã«åºããšãã°ã¢ããã¡ã
ã«ãïŒâã¢ãããšãã«ãããããªãã·ã¢ã«ãã«åº
ããšãã°ããããªãã·ã¡ãã«ãããããªãã·ãšã
ã«ãããšãã«ã眮æããšãã«ããŸãã¯ãã³ãžã«åº
ã§ããã 奜ãŸãããšã¹ãã«ã¯C1ãC6ã¢ã«ãã«ãšã¹ãã«
ã§ããã ããœã€ãã¢ã³é žããã®å¡©ããã³ãã®ãšã¹ãã«ã
ç¹ã«æå¹ãªäŒæç ã«ã¯æ§ç ããããããœã€ãã¢ã³
é žã¯Î²âã©ã¯ã¿ã æ§é ã®æèå€ã§ã¯ãªãã®ã§ãã
ãã·ãªã³ããã³ã»ãã¢ãã¹ããªã³æèå€ã䜿çšã§
ããªããªã³åçèã®Î²âã©ã¯ã¿ããŒãŒèæ ªã«å¯Ÿã
ãŠå¹æããããããœã€ãã¢ã³é žã¯ãŸãåŒåžåšç ã
ãšãã°æ ¢æ§æ°ç®¡æ¯çããã³çŽ°èæ§ãºã€èçãéãª
ã³èæ§å°¿éçããã³èºçã®æ²»çã«ãå¹æãããã
ç¹ã«åç©ã®å Žåãããœã€ãã¢ã³é žã¯çé·ä¿é²å€ãš
ããŠããŸãã¯ä¹³çã®ä¹³è ºçã®æ²»çããã³äžé¢é³¥ã
ãã¯ããªããã³ãã¿ã®ãããªåç©ã®ãã€ã³ãã©ãº
ãæ§äŒæç ã®æ²»çã«äœ¿çšããããšãã§ããã ãã€ã³ãã©ãºãèã«ãã€ãŠèµ·ããããœã€ãã¢ã³
é žããã³ãã®å¡©ããã³ãšã¹ãã«ãå¹æã瀺ã家ç
ããã³å®¶çŠœã®çŸç ãè¥å¹²ç€ºããšæ¬¡ã®åŠããªãã é³¥ é¡ ãã€ã³ãã©ãºãã»ã¬ãªã»ããã€ã«ã ïŒM.gall
âisepticumïŒâãã¯ããªããã³äžé¢é³¥ã®æ ¢æ§åŒ
åžåšç ãæ°ã®ãçŸæ£ïŒairsacculitiesïŒã ãã€ã³ãã©ãºãã»ã·ããã¢ãšïŒM.synoviaeïŒ
âæ°ã®ãçŸæ£ããã³æææ§æ»èç
ïŒinfectionssynovitisïŒ ãŠ ã· ãã€ã³ãã©ãºãã»ããã¹ïŒM.BovisïŒâä¹³çã®
ä¹³è ºçãåŒåžåšç ããã³é¢ç¯ç ãã€ã³ãã©ãºãã»ãã€ã¹ããŒã«ïŒM.disparïŒ
âåçã®èºç ãã¿é¡ ãã€ã³ãã©ãºãã»ã¹ã€ããŠãŒã¢ãã¢ãšïŒM.
suipneumoniaeïŒâè±ã®æµè¡æ§èºç ããºãé¡ ãã€ã³ãã©ãºãã»ãã«ã¢ãã¹ïŒM.pulmonisïŒ
âã©ããããã³ããã«ããºãã®èºç ãã€ã³ãã©ãºãã»ãã«ã¢ãã¹âJ.Bââããã«
ããºãã®é¢ç¯çäœµçº ã ã ãã€ã³ãã©ãºãã»ããŠãŒã¢ãã¢ãšïŒM.
pneumoniaeïŒâåçºæ§ç°åèºç ãã€ã³ãã©ãºãã»ããšã«ã¡ã³ã¿ã³ã¹ïŒM.
fermentansïŒ MWK14âãªãŠããæ§æ£è ã®é¢ç¯ããåé¢ããœ
ã€ãã¢ã³é žã¯ãã¿ãåçããã³ãããžã®ãããªå
ç©ã®æµè¡æ§èºçã«èªçºãããŠåŒåžåšã®å䜵çã
æã ã²ãããããã«ãããŒã©ïŒããã³ãã»ããã«
ïŒBordetella bronchisepticaïŒããã³ãã¹ããŠã¬
ã©ïŒã ã«ãã·ãïŒPasteurlla multotidaïŒèã«å¯Ÿ
ããŠãæèæ§ãæããã®ã§ããã®èºçã®æ²»çã«ç¹
ã«æçšã§ããã ããœã€ãã¢ã³é žãŸãã¯ãã®å¡©ãŸãã¯ãšã¹ãã«ã¯
家çå»è¬ãšããŠäœ¿çšãããããä»»æã®éœåã®ãã
æ¹æ³ã§èª¿å€ããããšãã§ããã çµæç©ã¯ä»»æã®çµè·¯ãéã€ãŠæäžããããã«èª¿
å€ããããšãã§ããæ²»çããããšããçŸç ã«ãã€
ãŠå€ãããçµæç©ã¯é å€ãã«ãã»ã«å€ãç²æ«å€ã
é¡ç²å€ãããããå€ãŸãã¯çµå£çšãŸãã¯æ» èéçµ
å£æº¶æ¶²ãŸãã¯æžæ¿å€ã®ãããªæ¶²äœè£œå€ã®åœ¢ã«ãã
ããšãã§ããã é å€ããã³ã«ãã»ã«å€ã¯åäœæäžåœ¢ãšããããš
ãã§ããéåžžã®äœè¬ãããšãã°ã·ããããã¢ã©ã
ã€ãŽã ããŒã©ãã³ããœã«ãããŒã«ããã©ã¬ã«ã³ã
ãŽã ãŸãã¯ããªããã«ãããªãã³ã®ãããªçµå
å€ãä¹³ç³ãã·ãšç³ãããŠã¢ãã³ã·æ®¿ç²ããªã³é žã«
ã«ã·ãŠã ããœã«ãããŒã«ãŸãã¯ã°ãªã·ã³ã®ãããª
å å¡«å€ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãæ»ç³ç²ãã
ãªãšãã¬ã³ã°ãªã³ãŒã«ãŸãã¯ã·ãªã«ã®ãããªé å€
補é ã®ãšãã®æœ€æ»å€ããã¬ã€ã·ãšæ®¿ç²ã®ãããªåŽ©
å£å€ããŸãã¯ã©ãŠãªã«ç¡«é žãããªãŠã ã®ãããªå»
çšã«äŸãåŸã湿最å€ãå ¥ããããšãã§ãããé å€
ã¯éåžžã®è£œè¬ã§å®æœãããŠããåšç¥ã®æ¹æ³ã«åŸã€
ãŠè¢«èŠããããšãã§ãããçµå£æ¶²äœè£œå€ã¯ãããš
ãã°æ°Žæ§ãŸãã¯æ²¹æ§ã®æžæ¿æ¶²ã溶液ã乳液ãã·ã
ããå€ãŸãã¯ãšãªãã·ã«ã®åœ¢ã«ããããšãã§ãã
ãããã¯ä¹Ÿç¥è£œåã®åœ¢ã«ããŠäœ¿çšåã«æ°Žãã®ä»ã®
é©åœãªããã¯ã«ã䜿çšããŠåæ§æããããšãã§ã
ãããã®çš®ã®æ¶²äœè£œå€ã¯éåžžã®æ·»å å€ãããšãã°
ãœã«ãããŒã«ãã·ããããã¡ãã«ã»ã«ããŒã¹ãã
ããŠç³ã·ãããããŒã©ãã³ãŸãã¯æ°ŽçŽ æ·»å é£ææ²¹
èã®ãããªæžæ¿å€ãã¬ã·ãã³ãã¢ããªã¬ã€ã³é žãœ
ã«ãã¿ã³ãŸãã¯ã¢ã©ãã€ãŽã ã®ãããªä¹³åå€ãæ
æ¡æ²¹ãåçã€ã·æ²¹ãã°ãªã»ãªã³ããããã¬ã³ãŸã
ã¯ãšãã«ã¢ã«ã³ãŒã«ã®ãšã¹ãã«ã®ãããªæ²¹ç¶ãšã¹
ãã«ã®ãããªé£ææ²¹ãå«ãéæ°Žæ§ããã¯ã«ãâ
ããããªãã·å®æ¯éŠé žã¡ãã«ãŸãã¯ãããã«ãŸã
ã¯ãœã«ãã³é žã®ãããªé²è å€ããã³å Žåã«ãã€ãŠ
ã¯é垞䜿çšãããŠãã颚å³æããã³çè²å€ãå«ã
ããšãã§ããã 座è¬ã¯éåžžã®åº§è¬çšåºå€ãããšãã°ã³ã³ã¢ãã¿
ãŒãã®ä»ã®ã°ãªã»ãªããå«ãã éçµå£æäžçšã®æ¶²ç¶åäœéæäžåœ¢ã¯ååç©ãã
ã³æ» èããã¯ã«ã奜ãŸããã¯æ°Žã䜿çšããŠèª¿è£œã
ãããååç©ã¯äœ¿çšããã¯ã«ããã³æ¿åºŠã«å¿ããŠ
ããã¯ã«æžæ¿ããããããããã¯æº¶è§£ãããã溶
液ã«ããå Žåã«ã¯ãååç©ã泚å°çšã®æ°Žã«ãšã
ãããéæ» èããŠããé©åœãªãã¢ã«ãŸãã¯ã¢ã³ã
ã«å å¡«ããã·ãŒã«ãããå±éšéº»é å€ãé²è å€ãã
ã³ç·©è¡å€ã®ãããªè£å©å€ãããã¯ã«ã«æº¶è§£ãããŠ
ãããšæå©ã§ãããçµæç©ã®å®å®æ§ãåäžããã
ããã«ããã¢ã«ã«å å¡«ããŠããåçµããæ°Žãç空
é€å»ããã次ã«åçµä¹Ÿç¥ç²æ«ããã¢ã«ã«å¯å°ãã
泚å°çšæ°Žã®ãã¢ã«ãæ·»ä»ããŠäœ¿çšåã«æ¶²äœè£œå€ã«
åæ§æãããéçµå£æžæ¿æ¶²ãå®è³ªçã«åæ§ã«èª¿è£œ
ãããããååç©ã溶解ãããªãã§ããã¯ã«ã«æž
æ¿ãããç¹ãšæ» èããéã§è¡ãªãããšãã§ããªã
ç¹ãšãã¡ãããååç©ã¯æ» èããã¯ã«ã«æžæ¿ãã
ãåã«é žåãšãã¬ã³ã«ãããããšã«ãã€ãŠæ» èã
ãããšãã§ãããååç©ãåäžã«åæ£ããããã
ãããã«ãçµæç©ã«è¡šé¢æŽ»æ§å€ãŸãã¯æ¹¿æœ€å€ãå ¥
ãããšæå©ã§ããã çµæç©ã¯æäžæ¹æ³ã«å¿ããŠæŽ»æ§ç©è³ª0.1ã99é
éïŒ ã奜ãŸããã¯10ã60ééïŒ ãå«ãããšãã§ã
ããçµæç©ãåäœæäžéã®åœ¢ã§ããå Žåã«ã¯åãŠ
ãããã¯å¥œãŸããã¯æŽ»æ§æå50ã500mgãå«ãã
æ人ã®æ²»çã«äœ¿çšããããšãã®æäžéã¯æäžçµè·¯
ããã³é »åºŠã«å¿ããŠã奜ãŸããã¯100mgãïŒïœïŒ
æ¥ãããšãã°250mgãïŒïœïŒæ¥ãšããã å¥æ³ãšããŠãããœã€ãã¢ã³é žãŸãã¯ãã®å¡©ãŸã
ã¯ãšã¹ãã«ã¯é£é€å šäœã®äžéšãšããŠæäžããããš
ãã§ããããã®å Žåååç©ã®äœ¿çšéã¯é£é€ã®ïŒé
éïŒ ã奜ãŸããã¯0.5ééïŒ ä»¥äžã§ãããåç©çš
ã®é£é€ã¯éåžžã®é£ç©ã«ååç©ãå ãããã®ã«ãã
ãããããã¯ååç©ããã¬ããã¯ã¹ã«å ããããš
ãã§ããã çç©åŠçããŒã¿ ïŒ ææµææ¢æ¿åºŠïŒMICå€ïŒ 第ïŒè¡šã¯ããœã€ãã¢ã³é žã®æèã¹ãã¯ãã«ã瀺
ããããœã€ãã¢ã³é žã¯ãããŠç¶çèå±ããã³å€§éš
åã®é£éç¶çèå±ã®çŽ°èã«å¯ŸããŠè¯å¥œãªæèæ§ã
æãããä»ã®æçç©è³ªã«å¯ŸããŠæµææ§ãæããè
æ ªãå«ãåçèå±èããã³ã€ã³ãã«ãšã³ã¶èã¯æ¬
ååç©ã«éåžžã«ææã§ãããç¹ã«ããã€ã³ãã©ãº
ãèæ ªã¯ããœã€ãã¢ã³é žã«éåžžã«ææã§ãããã
ãœã€ãã¢ã³é žã¯ã°ã©ã é°æ§èã«å¯ŸããŠæ¯èŒçã«äž
掻æ§ã§ããã
ãè¡šã
ïŒ è¡äžæ¿åºŠ
ïŒçš®ã®ããšãªã€ã被éšåç©çŸ€ã«ããœã€ãã¢ã³é
ž
ãæäžããçµæããæé«è¡äžæ¿åºŠããã³å°¿ååç
ã§è¡šããããã®ã第ïŒè¡šã«ç€ºãã
ãæäžããçµæããæé«è¡äžæ¿åºŠããã³å°¿ååç
ã§è¡šããããã®ã第ïŒè¡šã«ç€ºãã
ãè¡šã
ãè¡šã
ïŒ æ¯æ§
ããœã€ãã¢ã³é
žã¯ïŒçš®é¡ã®æäžæ³ã§ã©ãããã
ã³ããã«ããºãã®LD50å€ã瀺ã第ïŒè¡šã«ç€ºãã
ãããã«äœæ¯æ§ã瀺ãã
ã³ããã«ããºãã®LD50å€ã瀺ã第ïŒè¡šã«ç€ºãã
ãããã«äœæ¯æ§ã瀺ãã
ãè¡šã
ïŒ æãã€ã³ãã©ãºã掻æ§
ããœã€ãã¢ã³é
žã®Naå¡©ããã³ããœã€ãã¢ã³é
ž
ã¡ãã«ã¯ç¬¬ïŒè¡šã«ç€ºãããã«ã家çæºããæ¡åã
ãããã€ã³ãã©ãºãèã«å¯ŸããŠãè©Šéšç®¡è©Šéšã§è¯
奜ãªæãã€ã³ãã©ãºã掻æ§ã瀺ãã ããœã€ãã¢ã³é žã¯ããã«ããºãããã³ãã¯ããª
ã®ããã«å®éšçã«èªçºããããã€ã³ãã©ãºãææ
ã«ãããŠãçäœå ã§æŽ»æ§ã§ããã ããã«ããºãã䜿çšããïŒã€ã®å®éšã§ãé£ç¶ïŒ
æ¥éæ¯æ¥200mgïŒKgã®æ¿åºŠã§ç®äžæ³šå°æäžããã
ããœã€ãã¢ã³é žã¯ããããïŒå¹ã®ããã«ããºãäž
ïŒå¹ããã³ïŒå¹ã®ãã¡ïŒå¹ã§é¢ç¯çã®é²è¡ãé²æ¢
ãããïŒç¬¬ïŒè¡šåç §ïŒ ãã¯ããªã®ããã®å Žåãã€ã³ãã©ãºãã»ã·ãã
ã¢ãšã«ææããããããªã«200mgïŒKgã®æäžéã§
ïŒæ¥ïŒåçè泚å°æäžãããããœã€ãã¢ã³é žã¯ïŒ
矜ã®ãã¡ïŒçŸœã®æ°ã®ãç å·£ïŒairsac lesionsïŒã®
é²è¡ãé²æ¢ããããã€ã³ãã©ãºãã»ã·ããã¢ãšã¯
ããœã€ãã¢ã³é žæ²»çåŸã®ãã¹ãŠã®ããããªã®æ°ã®
ãç å·£ããååé¢ãããªãã€ããïŒç¬¬ïŒè¡šåç §ïŒ è©Šéšæ³ ïŒ ããœã€ãã¢ã³é žããã³ããœã€ãã¢ã³é žã¡ãã«ã®
æäœææ¢æ¿åºŠïŒMICïŒãæ°é³ä»£è¬æå¶è©Šéš ïŒTaylorâRobinsonïŒ1967ïŒã®ä¿®æ£æ³ã«ãã€
ãŠãã€ã¯ãã¿ã€ã¿ãŒæ¿ïŒMicrotitre plateïŒã§æž¬
å®ãããååç©ãæ» èè±ã€ãªã³æ°Žã§é次åžéããŠ
250ã0.5ÎŒïœïŒmlã®æ¿åºŠç¯å²ã®æº¶æ¶²ã調補ããã
ïŒïŒ ïŒïœïŒïœïŒã®ãããŠç³ããã³0.005ïŒ ïŒïœïŒ
ïœïŒã®ããšãã³ã¬ãããå«ããã€ã³ãã©ãºããã
ã¹ãããœã€ãã¢ã³é žæ°Žæº¶æ¶²ã«ããåžéãè£åãã
æ¿åºŠã§ããã€ã³ãã©ãºãã®çŽ104èéèœåœ¢æåäœ
ãåæ¿åºŠã®ããœã€ãã¢ã³é žæ°Žæº¶æ¶²ã«å ãããåã
ã€ã¯ãã¿ã€ã¿ãŒæ¿ã«ã¯ããœã€ãã¢ã³é žãå«ãŸãªã
现èææãŠãšã«ã现èææããŠããªããŠãšã«ãã
ã³PH調ç¯ãŠãšã«ãå«ãŸããããã€ã¯ãã¿ã€ã¿ãŒæ¿
ãã»ãããŒãã§ã·ãŒã«ãã37âã§ïŒæ¥éå¹é€ã
ããMICã¯ãã€ã³ãã©ãºãããããŠç³ãååã
ãããšã«ãã€ãŠèµ·ããã€ã³ãã©ãºãããã¹äžã®è²
ã®å€åãé²æ¢ããååç©ã®æäœæ¿åºŠã§ããã ïŒ ããã«ããºãã®M.ãã«ã¢ãã¹èèªçºé¢ç¯ç é¢ç¯çãèªçºããã®ã«äœ¿çšãããæ¹æ³ã¯
Hannanã1977幎ã«èšèŒããŠããæ¹æ³ã§ãã€ãŠã
M.ãã«ã¢ãã¹èæ ªâJBâ103ã105ïŒmlã®èéèœ
圢æåäœïŒCFUïŒmlïŒã®æ¿åºŠã§0.5mlããããã
ãäœé18ã22ïœã®ïŒãïŒå¹ã®NIHçš®ã®ã¡ã¹ã®ã
ãã«ããºã矀ã®å°Ÿéšè¡ç®¡ã«éè泚å°ããææåŸçŽ
ã¡ã«ãã®åŸã«ç¶ãïŒæ¥éã®éæ¯æ¥200mgïŒKgã®æ¿
床ã®ããœã€ãã¢ã³é žãç®äžæ³šå°æäžããã次ã«ã
ãã«ããºããïŒé±éã®éå®æçã«åè¢ã«ãããé¢
ç¯çã®çºéã«ã€ããŠèŠ³å¯ããã ïŒ ãã¯ããªã®ããã®M.ã·ããã¢ãšèªçºæ°ã®ã
çŸæ£ M.ã·ããã¢ãšATCCNo.25204ã®çŽ108CFUãå«
ãããã¹å¹é€æ¶²0.5mlãåµååŸïŒé±éã®ç¹æ®ç æº
èãå«ãŸãªãïŒSPFïŒã®çœè²ã¬ã°ãã³ã®ããïŒçŸœ
ã®çŸ€ã®å·Šè ¹è éšæ°ã®ãã«æ³šå°ããææåŸçŽã¡ã«ã
ãã®åŸïŒæ¥éé£ç¶ããŠïŒæ¥ïŒåãã€ããœã€ãã¢ã³
é žã200mgïŒKgã®æ¿åºŠã§çèå 泚å°æäžããææ
åŸïŒæ¥åŸã«ããããªã解åããæ°ã®ããèçŒã§ã
ã€ã³ãã©ãºãã«ããç å·£ã«ã€ããŠããŸãé¡åŸ®é¡ã§
M.ã·ããã¢ãšã®ååšã«ã€ããŠæ€æ»ãããã æ ç® ãçš®ã ã®å®¿äž»ã®ãã€ã³ãã©ãºãããã³ãã®æè
å€ã«å¯Ÿããæ床ãïŒTaylorâRobinsonïŒPost.
Grad.Med.J.ïŒ43ïŒSuppl.ãMarchãïŒ100ïŒ1967ïŒ ãã²ãèé¡åç©ã®ãã€ã³ãã©ãºãèªçºé¢ç¯çã«
ãããã¢ãŠãããªãªã³ãŽé žãããªãŠã ãã±ã©ãã³
é žéããã³çš®ã ã®ããã©ãµã€ã¯ãªã³ãïŒHannanïŒ
J.Med.Microbiol.ïŒ10ïŒ87ïŒ1977ïŒ
ã¡ãã«ã¯ç¬¬ïŒè¡šã«ç€ºãããã«ã家çæºããæ¡åã
ãããã€ã³ãã©ãºãèã«å¯ŸããŠãè©Šéšç®¡è©Šéšã§è¯
奜ãªæãã€ã³ãã©ãºã掻æ§ã瀺ãã ããœã€ãã¢ã³é žã¯ããã«ããºãããã³ãã¯ããª
ã®ããã«å®éšçã«èªçºããããã€ã³ãã©ãºãææ
ã«ãããŠãçäœå ã§æŽ»æ§ã§ããã ããã«ããºãã䜿çšããïŒã€ã®å®éšã§ãé£ç¶ïŒ
æ¥éæ¯æ¥200mgïŒKgã®æ¿åºŠã§ç®äžæ³šå°æäžããã
ããœã€ãã¢ã³é žã¯ããããïŒå¹ã®ããã«ããºãäž
ïŒå¹ããã³ïŒå¹ã®ãã¡ïŒå¹ã§é¢ç¯çã®é²è¡ãé²æ¢
ãããïŒç¬¬ïŒè¡šåç §ïŒ ãã¯ããªã®ããã®å Žåãã€ã³ãã©ãºãã»ã·ãã
ã¢ãšã«ææããããããªã«200mgïŒKgã®æäžéã§
ïŒæ¥ïŒåçè泚å°æäžãããããœã€ãã¢ã³é žã¯ïŒ
矜ã®ãã¡ïŒçŸœã®æ°ã®ãç å·£ïŒairsac lesionsïŒã®
é²è¡ãé²æ¢ããããã€ã³ãã©ãºãã»ã·ããã¢ãšã¯
ããœã€ãã¢ã³é žæ²»çåŸã®ãã¹ãŠã®ããããªã®æ°ã®
ãç å·£ããååé¢ãããªãã€ããïŒç¬¬ïŒè¡šåç §ïŒ è©Šéšæ³ ïŒ ããœã€ãã¢ã³é žããã³ããœã€ãã¢ã³é žã¡ãã«ã®
æäœææ¢æ¿åºŠïŒMICïŒãæ°é³ä»£è¬æå¶è©Šéš ïŒTaylorâRobinsonïŒ1967ïŒã®ä¿®æ£æ³ã«ãã€
ãŠãã€ã¯ãã¿ã€ã¿ãŒæ¿ïŒMicrotitre plateïŒã§æž¬
å®ãããååç©ãæ» èè±ã€ãªã³æ°Žã§é次åžéããŠ
250ã0.5ÎŒïœïŒmlã®æ¿åºŠç¯å²ã®æº¶æ¶²ã調補ããã
ïŒïŒ ïŒïœïŒïœïŒã®ãããŠç³ããã³0.005ïŒ ïŒïœïŒ
ïœïŒã®ããšãã³ã¬ãããå«ããã€ã³ãã©ãºããã
ã¹ãããœã€ãã¢ã³é žæ°Žæº¶æ¶²ã«ããåžéãè£åãã
æ¿åºŠã§ããã€ã³ãã©ãºãã®çŽ104èéèœåœ¢æåäœ
ãåæ¿åºŠã®ããœã€ãã¢ã³é žæ°Žæº¶æ¶²ã«å ãããåã
ã€ã¯ãã¿ã€ã¿ãŒæ¿ã«ã¯ããœã€ãã¢ã³é žãå«ãŸãªã
现èææãŠãšã«ã现èææããŠããªããŠãšã«ãã
ã³PH調ç¯ãŠãšã«ãå«ãŸããããã€ã¯ãã¿ã€ã¿ãŒæ¿
ãã»ãããŒãã§ã·ãŒã«ãã37âã§ïŒæ¥éå¹é€ã
ããMICã¯ãã€ã³ãã©ãºãããããŠç³ãååã
ãããšã«ãã€ãŠèµ·ããã€ã³ãã©ãºãããã¹äžã®è²
ã®å€åãé²æ¢ããååç©ã®æäœæ¿åºŠã§ããã ïŒ ããã«ããºãã®M.ãã«ã¢ãã¹èèªçºé¢ç¯ç é¢ç¯çãèªçºããã®ã«äœ¿çšãããæ¹æ³ã¯
Hannanã1977幎ã«èšèŒããŠããæ¹æ³ã§ãã€ãŠã
M.ãã«ã¢ãã¹èæ ªâJBâ103ã105ïŒmlã®èéèœ
圢æåäœïŒCFUïŒmlïŒã®æ¿åºŠã§0.5mlããããã
ãäœé18ã22ïœã®ïŒãïŒå¹ã®NIHçš®ã®ã¡ã¹ã®ã
ãã«ããºã矀ã®å°Ÿéšè¡ç®¡ã«éè泚å°ããææåŸçŽ
ã¡ã«ãã®åŸã«ç¶ãïŒæ¥éã®éæ¯æ¥200mgïŒKgã®æ¿
床ã®ããœã€ãã¢ã³é žãç®äžæ³šå°æäžããã次ã«ã
ãã«ããºããïŒé±éã®éå®æçã«åè¢ã«ãããé¢
ç¯çã®çºéã«ã€ããŠèŠ³å¯ããã ïŒ ãã¯ããªã®ããã®M.ã·ããã¢ãšèªçºæ°ã®ã
çŸæ£ M.ã·ããã¢ãšATCCNo.25204ã®çŽ108CFUãå«
ãããã¹å¹é€æ¶²0.5mlãåµååŸïŒé±éã®ç¹æ®ç æº
èãå«ãŸãªãïŒSPFïŒã®çœè²ã¬ã°ãã³ã®ããïŒçŸœ
ã®çŸ€ã®å·Šè ¹è éšæ°ã®ãã«æ³šå°ããææåŸçŽã¡ã«ã
ãã®åŸïŒæ¥éé£ç¶ããŠïŒæ¥ïŒåãã€ããœã€ãã¢ã³
é žã200mgïŒKgã®æ¿åºŠã§çèå 泚å°æäžããææ
åŸïŒæ¥åŸã«ããããªã解åããæ°ã®ããèçŒã§ã
ã€ã³ãã©ãºãã«ããç å·£ã«ã€ããŠããŸãé¡åŸ®é¡ã§
M.ã·ããã¢ãšã®ååšã«ã€ããŠæ€æ»ãããã æ ç® ãçš®ã ã®å®¿äž»ã®ãã€ã³ãã©ãºãããã³ãã®æè
å€ã«å¯Ÿããæ床ãïŒTaylorâRobinsonïŒPost.
Grad.Med.J.ïŒ43ïŒSuppl.ãMarchãïŒ100ïŒ1967ïŒ ãã²ãèé¡åç©ã®ãã€ã³ãã©ãºãèªçºé¢ç¯çã«
ãããã¢ãŠãããªãªã³ãŽé žãããªãŠã ãã±ã©ãã³
é žéããã³çš®ã ã®ããã©ãµã€ã¯ãªã³ãïŒHannanïŒ
J.Med.Microbiol.ïŒ10ïŒ87ïŒ1977ïŒ
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
â» ããã«ææçŽåŸã«ïŒåã次ã®æ¥ããé£ç¶ããŠ
ïŒæ¥éæ¯æ¥ïŒåãã€æäžããã
ïŒ æ°ã®ãå å¹é€
ïŒæ¥éæ¯æ¥ïŒåãã€æäžããã
ïŒ æ°ã®ãå å¹é€
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒïŒïŒ ã§ç€ºãããããœã€ãã¢ã³é žãŸãã¯ãã®éæ¯æ§å¡©ãŸ
ãã¯ãã®ãšã¹ãã«ã®æå¹éããã¢ãã€ã©ã¹å±ãã
ã³ãã€ã»ãªã¢å±ã®èã«èµ·å ããåŒåžåšç³»çŸç ãã
ã³æ§ç ããã³ãã€ã³ãã©ãºãã«èµ·å ããçŸç ã«ã
ãã€ããã以å€ã®åºä¹³åç©äžŠã³ã«ãã€ã³ãã©ãºã
ã«èµ·å ããçŸç ã«ããã€ã家犜ã«æäžããããšã
ããªããã以å€ã®åºä¹³åç©ããã³å®¶çŠœã®çŸç ãæ²»
çããæ¹æ³ã ïŒ æäžãããååç©ãããœã€ãã¢ã³é žãŸãã¯ã
ã®ã¢ã«ã«ãªéå±å¡©ãŸãã¯C1ãC6ã¢ã«ãã«ãšã¹ã
ã«ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ æäžãããååç©ãããœã€ãã¢ã³é žãŸãã¯ã
ã®ãããªãŠã å¡©ãŸãã¯ã¡ãã«ãšã¹ãã«ã§ããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åºä¹³åç©ããŠã·ãŸãã¯ãã¿ã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé ã第ïŒé ã®ãã¡ã®ããããäžã€ã®é èš
èŒã®æ¹æ³ã ïŒ çµå£æäžããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé
ã®ãã¡ã®ããããäžã€ã®é èšèŒã®æ¹æ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB44133/76A GB1577730A (en) | 1976-10-23 | 1976-10-23 | Treatment of infections with pseudomonicacid salts or esters thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5352629A JPS5352629A (en) | 1978-05-13 |
| JPS6312043B2 true JPS6312043B2 (ja) | 1988-03-17 |
Family
ID=10431945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12746977A Granted JPS5352629A (en) | 1976-10-23 | 1977-10-24 | Treating method of certain microbic infectious disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4196214A (ja) |
| JP (1) | JPS5352629A (ja) |
| AU (1) | AU515421B2 (ja) |
| BE (1) | BE859851A (ja) |
| DE (1) | DE2746974A1 (ja) |
| GB (1) | GB1577730A (ja) |
| IE (1) | IE45812B1 (ja) |
| NZ (1) | NZ185279A (ja) |
| PH (1) | PH12620A (ja) |
| ZA (1) | ZA775753B (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL56003A0 (en) * | 1977-12-03 | 1979-01-31 | Beecham Group Ltd | Novel thiol esters of monic acid, their preparation and pharmaceutical compositions containing them |
| EP0042233A1 (en) * | 1980-06-14 | 1981-12-23 | Beecham Group Plc | 13-oxo-monic acid and its salts and esters, process for their production, and compositions containing them |
| JPS58165617A (ja) * | 1982-03-27 | 1983-09-30 | æ ªåŒäŒç€Ÿããžã¯ã© | é»åã±âãã«ã®çµ¶çžæ¥ç¶éš |
| JPS58206518A (ja) * | 1982-05-13 | 1983-12-01 | ãâãã€ã ã»ã°ã«âãã»ãâãšã«ã·â | çé·ä¿é²å€ |
| GB8415579D0 (en) * | 1984-06-19 | 1984-07-25 | Beecham Group Plc | Compounds |
| GB8530796D0 (en) * | 1985-12-13 | 1986-01-22 | Beecham Group Plc | Pharmaceutical composition |
| GB9026873D0 (en) * | 1990-12-11 | 1991-01-30 | Beecham Group Plc | Novel compounds |
| US5594026A (en) * | 1990-12-11 | 1997-01-14 | Smithkline Beecham Group P.L.C. | Polymorphs of crystalline mupirocin |
| CN1203184C (zh) | 1999-02-03 | 2005-05-25 | æ奥çå°è¯åæéå ¬åž | ç»åŸ®çç©åŠæ¹æ³å¶å€ååèèé žaæççŽ çæ¹æ³ |
| DE02744598T1 (de) | 2001-06-21 | 2005-03-31 | Biogal Gyogyszergyar Rt. | Metabolisches kontrolliertes fermentationsverfahren zur herstellung von pseudomoninsÀure |
| HUP0600679A2 (en) * | 2001-12-28 | 2008-06-30 | Biogal Gyogyszergyar | Processes for preparing crystalline and amorphous mupirocin calcium and pharmaceutical compositions containing the same |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| ES2339682T3 (es) | 2004-06-01 | 2010-05-24 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Procedimiento para la preparacion de la forma amorfa de un farmaco. |
| CA2843093C (en) | 2014-02-20 | 2023-09-26 | National Research Council Of Canada | Neisseria gonorrhoeae therapeutic based on cmp-nonulosonate sugar |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1395907A (en) * | 1971-06-12 | 1975-05-29 | Beecham Group Ltd | Antibiotics |
| JPS5270083A (en) * | 1975-12-04 | 1977-06-10 | Yoshitomi Pharmaceut Ind Ltd | Manufacture of an antibiotics, trans-pseudomonic acid |
-
1976
- 1976-10-23 GB GB44133/76A patent/GB1577730A/en not_active Expired
-
1977
- 1977-09-26 ZA ZA00775753A patent/ZA775753B/xx unknown
- 1977-09-27 NZ NZ185279A patent/NZ185279A/xx unknown
- 1977-10-11 AU AU29575/77A patent/AU515421B2/en not_active Expired
- 1977-10-17 US US05/842,399 patent/US4196214A/en not_active Expired - Lifetime
- 1977-10-18 BE BE181844A patent/BE859851A/xx not_active IP Right Cessation
- 1977-10-19 DE DE19772746974 patent/DE2746974A1/de not_active Ceased
- 1977-10-21 PH PH20352A patent/PH12620A/en unknown
- 1977-10-21 IE IE2151/77A patent/IE45812B1/en unknown
- 1977-10-24 JP JP12746977A patent/JPS5352629A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1395907A (en) * | 1971-06-12 | 1975-05-29 | Beecham Group Ltd | Antibiotics |
| JPS5270083A (en) * | 1975-12-04 | 1977-06-10 | Yoshitomi Pharmaceut Ind Ltd | Manufacture of an antibiotics, trans-pseudomonic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5352629A (en) | 1978-05-13 |
| IE45812B1 (en) | 1982-12-01 |
| AU2957577A (en) | 1979-04-26 |
| ZA775753B (en) | 1978-08-30 |
| PH12620A (en) | 1979-07-05 |
| US4196214A (en) | 1980-04-01 |
| BE859851A (fr) | 1978-04-18 |
| IE45812L (en) | 1978-04-23 |
| GB1577730A (en) | 1980-10-29 |
| DE2746974A1 (de) | 1978-04-27 |
| NZ185279A (en) | 1980-08-26 |
| AU515421B2 (en) | 1981-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6312043B2 (ja) | ||
| US20040242546A1 (en) | Compositions and method for treating infection in cattle and swine | |
| CA1273579A (en) | Bactericidal formulations for use in the area of veterinary medicine | |
| JP4573411B2 (ja) | ãã€ã«ããã·ã«ã¿ã€ããã©ã€ãèªå°äœããã³ãããã®æãã¹ãã¬ã©èå€ãšããŠã®çšé | |
| US20060247184A1 (en) | Treatment and prophylaxis of diseases and infections pigs and poultry | |
| JP4165769B2 (ja) | ããã€ãã ããªã³èªå°äœã®ç£å»åŠçäœ¿çš | |
| US4186206A (en) | Treatment of swine dysentery | |
| US4206224A (en) | Treatment of infections | |
| US6486161B1 (en) | Use of rifamycin derivative for treating mastitis in a domestic animal | |
| CN113476431B (zh) | äžç§ç¯äžé ®è¡çç©åšå¶å€åšç©çšè¯äžçåºçš | |
| JP3636207B2 (ja) | å ç«è³ŠæŽ»ã»ææé²åŸ¡å€åã³ãã®è£œé æ¹æ³ | |
| JP2002513027A (ja) | ä¹³è ºçã®åŠçœ® | |
| CN101879177B (zh) | ç±ä¹æ°çšäºå¶å€æ²»çç±éŒ»è éžæèåŒèµ·ççŸç çè¯åççšé | |
| EP1001778B1 (en) | Use of a rifamycin derivative for treating mastitis in a domestic animal | |
| DK168042B1 (da) | Embonater af quinoloncarboxylsyrer og derivater deraf, en fremgangsmaade til deres fremstilling samt orale bactericide praeparater, fodermidler og drikkevand indeholdende disse embonater og en fremgangsmaade til praeparaternes fremstilling | |
| JPS633846B2 (ja) | ||
| JP6921805B2 (ja) | ãŠã·ä¹³è ºçã®æ²»çã«äœ¿çšããããã®ãªãœãã¯ãã³ | |
| Mishra et al. | Methicillin-Resistant Staphylococcus aureus: A Livestock Concern | |
| AT366038B (de) | Verfahren zur herstellung von neuen verbindungen | |
| KR100516418B1 (ko) | í룚ë¡ë®€ížëŠ°ì ë첎ìììíì ì©ë | |
| US4170645A (en) | Antibacterial agent BM123γ, salts and alkyl derivatives thereof for the control of shipping fever in cattle | |
| JPH11116474A (ja) | æèæ§åå€ | |
| US4170647A (en) | Method for the control of Arizona hinshawii in poultry with an alkylated BM123γ-type antibiotic | |
| Cuckler et al. | Nithiazide: 3. Tolerance studies in poultry | |
| AU2012363652A1 (en) | A method for treating Lyme disease |